转移性甲状腺癌的新治疗方法。

New therapeutic approaches for metastatic thyroid carcinoma.

作者信息

Baudin Eric, Schlumberger Martin

机构信息

Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, and Faculté de Médecine Paris Sud, Villejuif, France.

出版信息

Lancet Oncol. 2007 Feb;8(2):148-56. doi: 10.1016/S1470-2045(07)70034-7.

DOI:10.1016/S1470-2045(07)70034-7

PMID:17267329

Abstract

Treatment of metastatic differentiated thyroid cancer (DTC) includes the use of radioiodine and suppressive thyroid hormone treatment. A third of patients with distant metastases (who have radioiodine uptake, are younger than 40 years, have small metastases, and have well differentiated thyroid tumour) can be cured with radioiodine treatment. For other patients, there are no effective treatment modalities. However, the recent availability of molecularly targeted treatments has led to changes in the treatment strategy for DTC in patients with distant metastases, especially in those who are resistant to radioiodine treatment.

摘要

转移性分化型甲状腺癌（DTC）的治疗包括使用放射性碘和抑制性甲状腺激素治疗。三分之一有远处转移（有放射性碘摄取、年龄小于40岁、转移灶小且甲状腺肿瘤分化良好）的患者可通过放射性碘治疗治愈。对于其他患者，没有有效的治疗方式。然而，分子靶向治疗的近期出现已导致远处转移的DTC患者治疗策略的改变，尤其是那些对放射性碘治疗耐药的患者。